Introduction {#s001}
============

P[atients with acute traumatic spinal cord injuries]{.smallcaps} (TSCIs) often experience severe loss of function and profoundly impaired quality of life, and the development of interventions to improve motor recovery is critically important.^[@B1],[@B2]^ More than 500,000 people suffer acute TSCIs worldwide each year, and global prevalence is expected to increase.^[@B3]^

In the landmark Second National Spinal Cord Injury Study (NASCIS-II), 437 participants with acute TSCIs were randomized to an initial bolus of 30 mg/kg of methylprednisolone (MPS) followed by an infusion of 5.4 mg/kg/h for 23 h versus either naloxone or placebo.^[@B6],[@B7]^ Although subgroup analyses suggested a small benefit attributable to MPS for motor recovery, other studies reported conflicting results and utilization has declined sharply in the last decade.^[@B8]^ Potential harms of MPS include risks for infections and gastrointestinal bleeding, potentially leading to increased mortality.^[@B1],[@B13]^ Most current guidelines do not recommend routine administration of MPS for acute TSCIs.^[@B13]^

Systematic reviews and meta-analyses are powerful tools that can synthesize conflicting literature and inform clinical practice, but they require rigorous methodology and must be frequently updated to avoid misleading conclusions.^[@B16],[@B17]^ New primary studies have been recently published, and previous meta-analyses evaluating MPS for patients with TSCIs have not addressed confidence in the quality of the evidence used for the pooled effect estimates.^[@B1],[@B8],[@B18]^ Therefore, we aimed to determine whether MPS improves motor recovery and is associated with an increase in adverse events (AEs) in patients with acute TSCIs in comparison to placebo or no treatment.

Methods {#s002}
=======

We performed a systematic review and meta-analysis according to the methods of the Cochrane Handbook for Systematic Reviews of Interventions, and we report according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.^[@B21],[@B22]^

Eligibility criteria {#s003}
--------------------

We included all randomized, controlled trials (RCTs) and controlled observational studies that compared MPS against placebo or no treatment in adult patients with acute TSCIs. Studies that reported exclusively on pediatric patients (less than 18 years of age) and studies of corticosteroids other than MPS were excluded. Studies that combined pediatric patients with adult patients were included. No exclusions were made on the basis of open versus closed injuries, language, publication status, timing of outcome assessment, setting, or regimen of MPS.

Identification of studies {#s004}
-------------------------

We searched MEDLINE (1946 to present), EMBASE (1974 to present), and The Cochrane Library (no date limit) on June 6, 2015 using MeSH and EMTREE headings and subheadings in various combinations, supplemented with free text ([Appendix 1](#a001){ref-type="app"}). We also reviewed reference lists from included studies and previous reviews, consulted with experts, and used the "related articles" feature in PubMed. To identify potential unpublished studies, we searched clinicaltrials.gov and reviewed annual conference proceedings from 2012 to the present for the North American Spine Society, the Spine Society of Europe, and the Canadian Spine Society.

Two reviewers (N.E., E.B.C.) independently screened all titles and abstracts and then screened the full texts of potentially eligible studies for final inclusion. Studies in languages other than English were translated. All discrepancies were resolved by consensus.

Data extraction {#s005}
---------------

The two reviewers independently evaluated risk of bias for each study using the Cochrane Collaboration\'s Risk of Bias tool for RCTs and the Methodological Index for Non-Randomized Studies (MINORS) for observational studies, and all discrepancies were resolved by consensus.^[@B21],[@B23]^

We classified outcomes by consensus as critical, important but not critical, or of limited importance to patients and decision makers, and we extracted data for those outcomes considered critical or important.^[@B21]^ Motor recovery and specific AEs (mortality, sepsis, pneumonia, gastrointestinal bleeding, decubitus ulcer, urinary tract infection, venous thromboembolism, and surgical site infection) were considered critical or important based on clinical significance and previous literature.^[@B24]^ Sensory recovery, length of stay, hyperglycemia, and other outcomes were considered of limited importance.

The two reviewers independently extracted the following data points using piloted electronic data forms: study design; first author; journal; year of publication; patient characteristics; surgical cointervention and surgical timing; injury severity; sample size and losses in each group; duration of follow-up; MPS regimen; motor recovery outcomes; and AEs. Scales for motor recovery outcomes included International Standards for Neurologic Classification of Spinal Cord Injury American Spinal Injury Association (ASIA) total motor scores (continuous) and improvement by one grade or more on the Frankel or ASIA Impairment Scale (AIS; dichotomous).^[@B27]^

We contacted authors and reviewed data reported in previous meta-analyses for clarifications when needed.^[@B8]^ We estimated standard deviations (SDs) for motor score improvement, when necessary, by imputing the median SDs for all patients that received the same treatment (steroids vs. no steroids) from all studies that reported on the same outcome (motor score improvement).^[@B21]^ When studies investigated additional interventions, we extracted outcome data only for comparisons of MPS versus placebo or no treatment.

Data synthesis {#s006}
--------------

We pre-specified that we would not pool data from RCTs with data from observational studies,^[@B21],[@B28]^ and we pre-specified subgroup hypotheses that we would test to explain potential high heterogeneity: cervical versus thoracolumbar injuries; complete (AIS A) versus incomplete (AIS B/C/D) injuries; presence and timing of surgical cointervention; and risk of bias.^[@B16],[@B29]^ We also planned subgroup analyses for motor recovery outcomes including only studies in which MPS was administered within 8 h of injury regardless of heterogeneity because of established clinical interest.^[@B1],[@B8]^ We pooled motor recovery data at follow-up durations of 6 months or earlier (short-term) and greater than 6 months (long-term), and AE data at final follow-up from each study.^[@B1],[@B6],[@B24],[@B30],[@B32]^ We used the numbers of participants reported as followed up at each specific time point in each trial, where possible.

We used the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach to evaluate confidence in the pooled effect estimates.^[@B16],[@B33]^ According to GRADE, data from RCTs are considered high-quality evidence, but can be rated down according to risk of bias, imprecision, inconsistency, indirectness, or publication bias. Data from observational studies are considered low-quality evidence, but can be rated up because of a large treatment effect, evidence of a dose-response relationship, or if all plausible biases would not undermine the conclusions. We rated down for imprecision if the 95% confidence intervals (CIs) failed to exclude benefit or harm and if the pooled sample would have been underpowered to detect the point estimate (Optimal Information Size criterion).^[@B34]^ We rated down for inconsistency if statistically significant heterogeneity could not be explained by our pre-specified subgroup hypotheses.^[@B35]^

Statistical analysis {#s007}
--------------------

We quantified interobserver agreement for the reviewers\' assessments using Cohen\'s kappa and interpreted values according to Landis and Koch as: 0, poor; 0.01--0.20, slight; 0.21--0.40, fair; 0.41--0.60, moderate; 0.61--0.80, substantial; and 0.81--1.00, almost perfect.^[@B36]^ We combined outcome data according to the inverse variance method using a random effects model.^[@B21]^ We report pooled estimates as mean differences (MDs) with 95% CIs for continuous outcomes and risk ratios (RRs) with 95% CIs for dichotomous outcomes. We constructed funnel plots to assess for publication bias; we quantified heterogeneity using the chi-squared test and the I^2^ statistic. We planned sensitivity analyses to test the importance of estimated data by omitting studies requiring estimation and to test the importance of losses to follow-up across a range of plausible assumptions about the nature of any losses.^[@B37]^ Tests of significance were two-tailed and *p* values \<0.05 were considered significant. All analyses were performed using IBM SPSS (version 21; SPSS, Inc., Chicago IL) and Review Manager software (version 5.3; The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark).

Results {#s008}
=======

Included studies {#s009}
----------------

Our search strategy identified 2062 potential articles, 82 of which we reviewed as full texts ([Fig. 1](#f1){ref-type="fig"}). Thereafter, we included four RCTs (*n* = 548 participants)^[@B6],[@B38]^ and 17 controlled observational studies (*n* = 3967)^[@B16],[@B19],[@B20],[@B41]^ that compared MPS to placebo or no treatment in adult patients with acute TSCIs. Interobserver agreement was substantial for screening of titles and abstracts (kappa = 0.75) and almost perfect for review of full texts (kappa = 0.95). We used a previous meta-analysis^[@B8]^ to clarify motor scores for three studies^[@B6],[@B38],[@B39]^ and AEs for one study.^[@B38]^ Contact with authors led to clarification of AEs and quality assessment for one study.^[@B53]^

![Flow of articles through the systematic review. TSCI, traumatic spinal cord injury.](fig-1){#f1}

Of the four RCTs, two compared the NASCIS-II regimen of MPS against placebo^[@B6],[@B40]^ and two against no treatment^[@B38],[@B39]^ ([Table 1](#T1){ref-type="table"}). Two reported on motor score improvement at short-term follow-up and two at long-term follow-up,^[@B7],[@B39]^ and all four reported on at least one AE of interest. Three reported that all participants were treated within 8 h of their injuries and one reported that only 45% were treated within 8 h, but had published subgroup data available.

###### 

[Included Studies]{.smallcaps}

  *Authors*                          *Year*       *Size*   *Follow-up (months)*   *Mean age (years)*   *Males (%)*   *Cervical (%)*   *Open (%)*   *Surgery (%)*   *Complete (%)*   *MPS regimen*   *Within 8 h (%)*   *Outcomes*
  ---------------------------------- ------------ -------- ---------------------- -------------------- ------------- ---------------- ------------ --------------- ---------------- --------------- ------------------ ------------------------------------------
  Randomized, controlled trials                                                                                                                                                                                        
   Bracken et al.^[@B6; @B7; @B8]^   1990/ 1992   333      6, 12                  NR                   86            NR               1            99              62               NASCIS-II       45                 Motor scores, adverse events
   Otani et al.^[@B38]^              1994         117      6                      NR                   NR            NR               NR           NR              NR               NASCIS-II       100                Motor scores, adverse events
   Pointillart et al.^[@B39]^        2000         52       12                     30                   90            NR               0            NR              45               NASCIS-II       100                Motor scores, adverse events
   Matsumoto et al.^[@B40]^          2001         46       24                     61                   91            100              0            0               33               NASCIS-II       100                Adverse events
  Observational studies                                                                                                                                                                                                
   Prendergast et al.^[@B51]^        1994         54       2                      36                   80            NR               57           NR              46               NASCIS-II       NR                 Motor scores, adverse events
   Gäbler et al.^[@B41]^             1995         144      \>12                   39                   74            39               NR           100             42               NASCIS-II       100                Frankel ≥1, adverse events
   George et al.^[@B53]^             1995         145      \<1                    34                   77            55               9            68              64               NASCIS-II       NR                 Adverse events
   Gerhart et al.^[@B42]^            1995         278      NR                     NR                   NR            55               6            NR              NR               NASCIS-II       NR                 Frankel ≥1
   Yokota et al.^[@B52]^             1995         38       \<1                    37                   87            63               NR           61              NR               NASCIS-II       100                Motor scores, adverse events
   Levy et al.^[@B43]^               1996         236      6                      26                   94            22               100          7               55               NASCIS-II       100                Frankel ≥1, adverse events
   Heary et al.^[@B44]^              1997         224      56                     26                   91            30               100          15              75               NASCIS-II       100                Motor scores, Frankel ≥1, adverse events
   Gerndt et al.^[@B45]^             1997         140      NR                     32                   77            56               0            77              NR               NASCIS-II       100                Adverse events
   Pollard et al.^[@B46]^            2003         304      24                     NR                   NR            100              NR           78              0                NASCIS-II       NR                 Motor scores
   Tsutsumi et al.^[@B47]^           2006         70       6                      51                   89            100              NR           NR              61               NASCIS-II       100                Motor scores, adverse events
   Suberviola et al.^[@B48]^         2008         82       \<1                    42                   84            54               NR           21              54               NASCIS-II       100                Frankel ≥1, adverse events
   Ito et al.^[@B49]^                2009         79       3                      58                   80            100              NR           72              27               NASCIS-II       100                Motor scores, AIS ≥1, adverse events
   Aomar Millan et al.^[@B54]^       2011         96       6                      36                   79            NR               NR           NR              47               NASCIS-II       100                Adverse events
   Chikuda et al.^[@B19]^            2014         1624     \<1                    61                   79            100              NR           23              NR               "High-dose"     NR                 Adverse events
   Khan et al.^[@B20]^               2014         350      NR                     44                   76            68               NR           100             43               NASCIS-II       100                Adverse events
   Sribnick et al.^[@B50]^           2014         15       22                     37                   60            100              NR           100             60               "High-dose"     NR                 AIS ≥1, adverse events
   Evaniew et al.^[@B1]^             2015         88       4                      45                   88            73               NR           86              45               NASCIS-II       100                Motor scores, adverse events

MPS, methylprednisolone; NR, not reported; NASCIS-II, Second National Spinal Cord Injury Study; AIS, ASIA Impairment Scale.

Of the 17 observational studies, 15 compared the NASCIS-II regimen of MPS against no treatment and two compared "high-dose" MPS against no treatment ([Table 1](#T1){ref-type="table"}). Seven reported on motor score improvement, of which five did so at short-term follow-up and two at long-term follow-up. Seven reported on improvement by one grade or more on the Frankel or ASIA Impairment Scale, including three at short-term follow-up and two at long-term follow-up. One reported on motor grade improvement at the "time of discharge" and was pooled at short-term follow-up, and one did not report follow-up duration for motor recovery and was pooled at long-term follow-up. Fifteen observational studies reported on at least one of the AEs of interest.

Risk of bias {#s010}
------------

All four RCTs were at unclear risk of bias for sequence generation, allocation concealment, and addressing incomplete outcome data, and low risk for selective reporting ([Appendix 2](#a002){ref-type="app"}). Two were at low risk and two were at high risk for blinding. None adequately reported loss to follow-up. One study was at high risk because there were a large number of unexplained post-randomization exclusions.

Fifteen of the 17 observational studies were retrospective and five used historical, rather than contemporary, control groups ([Appendix 2](#a002){ref-type="app"}). None incorporated unbiased assessment of outcomes, 14 did not demonstrate similarity at baseline, and only two performed adjusted analyses, nine did not specify consecutive patient enrollment, and 11 did not report losses to follow-up.

Our funnel plots to detect publication bias were symmetric, but the small number of studies for each outcome limited interpretability ([Appendix 3](#a003){ref-type="app"}).^[@B21]^

Motor recovery {#s011}
--------------

MPS was not associated with a significant motor score improvement at short-term follow-up according to evidence from two RCTs (414 participants; MD, 1.19; 95% CI, −2.33 to 4.71; *p* = 0.51; heterogeneity, *p* = 0.23, I^2^ = 30%; low confidence) and five observational studies (308 participants; MD, 3.04; 95% CI, −2.81 to 8.90; *p* = 0.31; heterogeneity, *p* \< 0.05, I^2^ = 77%; very low confidence; [Fig. 2A](#f2){ref-type="fig"}). MPS was also not associated with a significant motor score improvement at long-term follow-up according to evidence from two RCTs (335 participants; MD, −1.11; 95% CI, −4.75 to 2.53; *p* = 0.55; heterogeneity, *p* = 0.52, I^2^ = 0%; low confidence) and two observational studies (528 participants; MD, 1.37; 95% CI, −3.08 to 5.83; *p* = 0.55; heterogeneity, *p* = 0.26, I^2^ = 22%; very low confidence; [Fig. 2b](#f2){ref-type="fig"}). We rated down the quality of the evidence for motor score improvement to low for RCTs because of risk of bias and imprecision, and to very low for observational studies because of study design, risk of bias, and imprecision ([Table 2](#T2){ref-type="table"}). Heterogeneity among the observational studies with short-term outcomes was resolved by including only those studies in which all patients received surgical cointervention according to a pre-specified subgroup analysis (167 participants, two studies; MD, −0.99; 95% CI, −6.02 to 4.04; *p* = 0.70; heterogeneity, *p* = 0.85, I^2^ = 0%; very low confidence).

![Pooled effect estimates for motor score improvement with methylprednisolone versus placebo or no treatment. (**A**) Short-term follow-up. (**B**) Long-term follow-up. SD, standard deviation; CI, confidence interval; MPS, methylprednisolone.](fig-2){#f2}

###### 

[Summary of Findings: Methylprednisolone vs. Placebo or No Treatment for Patients With Acute Traumatic Spinal Cord Injuries]{.smallcaps}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Outcome*                                              *Follow-up*       *Data source*   *No. of participants*                                *Quality of evidence^[a](#tf2){ref-type="table-fn"}^(GRADE)*   *Anticipated effects*
  ------------------------------------------------------ ----------------- --------------- ---------------------------------------------------- -------------------------------------------------------------- -----------------------------------------------------------------------------------------
  Motor score                                            Short             RCT             414 (2 studies)^[@B6],[@B38]^                        **LOW**\                                                       No significant difference between groups (MD, 1.19; 95% CI, −2.33 to 4.71; *p* = 0.51)
                                                                                                                                                Risk of bias, imprecision                                      

                                                                           OBS             308 (5 studies)^[@B1],[@B47],[@B49],[@B51],[@B52]^   **VERY LOW**\                                                  No significant difference between groups (MD, 3.04; 95% CI, −2.81 to 8.90; *p* = 0.31)
                                                                                                                                                Study design, risk of bias, imprecision                        

                                                         Long              RCT             335 (2 studies)^[@B6],[@B39]^                        **LOW**\                                                       No significant difference between groups (MD, −1.11; 95% CI, −4.75 to 2.53; *p* = 0.55)
                                                                                                                                                Risk of bias, imprecision                                      

                                                                           OBS             528 (2 studies)^[@B44],[@B46]^                       **VERY LOW**\                                                  No significant difference between groups (MD, 1.37; 95% CI, −3.08 to 5.83; *p* = 0.55)
                                                                                                                                                Study design, risk of bias, imprecision                        

  Improvement by ≥1 Frankel/AIS grade                    Short             OBS             675 (4 studies)^[@B42],[@B43],[@B48],[@B49]^         **VERY LOW**\                                                  No significant difference between groups (RR, 1.27; 95% CI, 0.75−2.17; *p* = 0.37)
                                                                                                                                                Study design, risk of bias, imprecision, inconsistency         

                                                         Long              OBS             383 (3 studies)^[@B41],[@B44],[@B50]^                **VERY LOW**\                                                  No significant difference between groups (RR, 0.84; 95% CI, 0.53−1.33; *p* = 0.46)
                                                                                                                                                Study design, risk of bias, imprecision                        

  Total adverse Events^[b](#tf6){ref-type="table-fn"}^   Up to 24 months   RCT             595 (4 studies)^[@B6],[@B38],[@B39],[@B40]^          **LOW**\                                                       No significant difference between groups (RR, 1.65; 95% CI, 0.62−4.41; *p* = 0.32)
                                                                                                                                                Risk of bias, imprecision,                                     

                                                         Up to 56 months   OBS             3347 (14 studies)~1,19,20,41,43--45,47--51,53,54,~   **VERY LOW**\                                                  No significant difference between groups (RR, 1.23; 95% CI, 1.00--1.52; *p* = 0.05)
                                                                                                                                                Study design, risk of bias                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

Composite of total adverse events: mortality, sepsis, pneumonia, gastrointestinal bleeding, decubitus ulcer, urinary tract infection, venous thromboembolism, and surgical site infection.

AIS, ASIA Impairment Scale; RCT, randomized, controlled trial; OBS, observational study; GRADE, Grades of Recommendation, Assessment, Development, and Evaluation; MD, mean difference; RR, relative risk; CI, confidence interval.

According to evidence from observational studies only, MPS was not associated with a significant improvement by one grade or more on the Frankel or ASIA Impairment Scale at short-term follow-up (675 participants, four studies; RR, 1.27; 95% CI, 0.75--2.17; *p* = 0.37; heterogeneity, *p* \< 0.05, I^2^ = 76%; very low confidence; [Fig. 3A](#f3){ref-type="fig"}) or long-term follow-up (383 participants, three studies; RR, 0.84; 95% CI, 0.53--1.33; *p* = 0.46; heterogeneity, *p* = 0.96, I^2^ = 0%; [Fig. 3b](#f3){ref-type="fig"}). Heterogeneity at short-term follow-up was not explained by our pre-specified subgroup hypotheses, so we rated down the quality of the evidence for inconsistency.

![Pooled effect estimates for improvement by one grade or more on the Frankel or ASIA Impairment Scale with methylprednisolone versus placebo or no treatment. (**A**) Short-term follow-up. (**B**) Long-term follow-up. ASIA, American Spinal Injury Association; CI, confidence interval; MPS, methylprednisolone.](fig-3){#f3}

According to evidence from RCTs, MPS initiated within 8 h of injury was associated with a significant motor score improvement at short-term follow-up (250 participants, two studies; MD, 4.46; 95% CI, 0.97--7.94; *p* = 0.01; heterogeneity, *p* = 0.81, I^2^ = 0%; low confidence), but not at long-term follow-up (177 participants, two studies; MD, 1.97; 95%, −7.78 to 11.73; *p* = 0.69; heterogeneity, *p* = 0.16, I^2^ = 50; low confidence; [Appendix 4](#a004){ref-type="app"}). According to evidence from observational studies, MPS initiated within 8 h of injury was not associated with a significant motor score improvement at short-term follow-up (275 participants, four studies; MD, 4.48; 95% CI, −2.49 to 11.45; *p* = 0.21; heterogeneity, *p* \< 0.05, I^2^ = 81%; very low confidence) or long-term follow-up (224 patients, one study; MD, −1.80; 95% CI, −8.79 to 5.19; *p* = 0.61; very low confidence) and was not associated with a significant improvement by one grade or more on the Frankel or ASIA Impairment Scale at short-term follow-up (675 participants, four studies; RR, 1.27; 95% CI, 0.75--2.17; *p* = 0.37; heterogeneity, *p* \< 0.05, I^2^ = 76%; very low confidence) or long-term follow-up (368 participants, two studies; RR, 0.86; 95% CI, 0.53--1.38; *p* = 0.53; heterogeneity, *p* = 0.97, I^2^ = 0%; very low confidence). We rated down the quality of the evidence for motor score improvement when MPS was initiated within 8 h of injury to low for RCTs because of risk of bias and imprecision, and to very low for observational studies because of study design, risk of bias, and imprecision

Adverse events {#s012}
--------------

MPS was not associated with significantly increased risks for mortality, sepsis, pneumonia, decubitus ulcer, urinary tract infection, venous thromboembolism, surgical site infection, or total AEs according to pooled evidence from RCTs and observational studies ([Table 3](#T3){ref-type="table"}; [Appendix 5](#a005){ref-type="app"}). Evidence from observational studies suggested a significantly increased risk for gastrointestinal bleeding (2857 participants, nine studies; RR, 2.18; 95% CI, 1.13--4.19; *p* = 0.02; heterogeneity, *p* = 0.17, I^2^ = 33%; very low confidence), but evidence from RCTs did not (444 participants, three studies; RR, 1.99; 95% CI, 0.74--2.13; *p* = 0.40; heterogeneity, *p* = 0.54, I^2^ = 0%). The quality of the evidence for all AEs was rated down to low for RCTs because of risk of bias and imprecision, and to very low for observational studies because of study design and risk of bias ([Table 2](#T2){ref-type="table"}).

###### 

[Adverse Events]{.smallcaps}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Outcome*                                              *Pooled effect estimate from Randomized, controlled trials*   *Pooled effect estimate from observational studies*
  ------------------------------------------------------ ------------------------------------------------------------- -----------------------------------------------------
  Mortality                                              RR, 0.55; 95% CI, 0.24--1.28; *p* = 0.17\                     RR, 0.73; 95% CI, 0.54--1.07; *p* = 0.10\
                                                         484 participants (2 studies)                                  2624 participants (10 studies)

  Sepsis                                                 RR, 1.11; 95% CI, 0.52--2.40; *p* = 0.79\                     RR, 1.44; 95% CI, 0.72--2.89; *p* = 0.30\
                                                         444 participants (3 studies)                                  2078 participants (5 studies)

  Pneumonia                                              RR, 1.26; 95% CI, 0.74--2.13; *p* = 0.40\                     RR, 1.19; 95% CI, 0.74--1.91; *p* = 0.47\
                                                         444 participants (3 studies)                                  2689 participants (10 studies)

  Gastrointestinal bleeding                              RR, 1.99; 95% CI, 0.74--5.37; *p* = 0.17\                     **RR, 2.18; 95% CI, 1.13--4.19;*p* = 0.02\
                                                         444 participants (3 studies)                                  **2857 participants (9 studies)

  Decubitus ulcer                                        RR, 0.94; 95% CI, 0.60--1.46; *p* = 0.78\                     RR, 2.07; 95% CI, 0.96--4.45; *p* = 0.06\
                                                         379 participants (2 studies)                                  218 participants (2 studies)

  Urinary tract infection                                RR, 1.01; 95% CI, 0.81--1.27; *p* = 0.91\                     RR, 1.01; 95% CI, 0.77--1.33; *p* = 0.92\
                                                         444 participants (3 studies)                                  2449 participants (8 studies)

  Venous thromboembolism                                 RR, 0.89; 95% CI, 0.41--1.94; *p* = 0.77\                     RR, 1.10; 95% CI, 0.60--2.00; *p* = 0.76\
                                                         333 participants (1 study)                                    2232 participants (5 studies)

  Surgical site infection                                RR, 2.11; 95% CI, 0.81--5.49; *p* = 0.13\                     RR, 0.88; 95% CI, 0.44--1.78; *p* = 0.73\
                                                         333 participants (1 study)                                    839 participants (7 studies)

  Total adverse events^[a](#tf9){ref-type="table-fn"}^   RR, 1.65; 95% CI, 0.62--4.41; *p* = 0.32\                     RR, 1.23; 95% CI, 1.00--1.52; *p* = 0.05\
                                                         595 participants (4 studies)                                  3347 participants (14 studies)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bolded results = statistically significant.

Composite of total adverse events: mortality, sepsis, pneumonia, gastrointestinal bleeding, decubitus ulcer, urinary tract infection, venous thromboembolism, and surgical site infection.

RR = relative risk; CI, confidence interval.

Sensitivity analyses {#s013}
--------------------

Our results were robust in sensitivity analyses to test the importance of estimated data ([Appendix 6](#a006){ref-type="app"}). Sensitivity analyses to test the importance of loss to follow-up were not performed because they were adequately reported only in five observational studies ([Appendix 2](#a002){ref-type="app"}).

Discussion {#s014}
==========

According to evidence from RCTs and controlled observational studies, MPS did not significantly improve long-term motor score recovery or recovery by at least one motor grade in patients with acute TSCIs in comparison to placebo or no treatment. Limited data suggested short-term motor score improvements if MPS was administered within 8 h of injury, but there was no significant benefit after more than 6 months. Evidence from observational studies suggested an association between MPS and an increased rate of gastrointestinal bleeding, but evidence from RCTs did not. The risks for other AEs were not significantly different between groups. The quality of the evidence for all outcomes was low or very low, which means that confidence in the effect estimates is limited and the true effects may be substantially different.

Limitations {#s015}
-----------

We included evidence from RCTs and evidence from controlled observational studies, and this approach risked trading off imprecise but unbiased estimates for precise but biased estimates.^[@B21]^ Statistical heterogeneity was minimal for most outcomes, but it is plausible that unreported differences in treatment decisions, administration of cointerventions, timing of baseline neurological examinations, or methods of outcomes assessment could have introduced important variability.^[@B25],[@B55],[@B56]^ For example, patients given MPS within 8 h of their injuries would be most likely to have had their baseline neurological exams performed within 8 h of injury, whereas those who did not receive MPS may have been treated outside that window and had their baseline examinations delayed. Differential timing of baseline examinations could therefore bias motor recovery outcomes in favor of MPS by creating a greater opportunity to recovery.^[@B1]^

In order to avoid unacceptable error and misleading conclusions, we presented the effect estimates from RCTs and observational studies separately and we rated down confidence for each study design when risk of bias was unclear or high.^[@B21],[@B33]^ Given that poorly designed or poorly executed RCTs can sometimes be more problematic than well-designed observational studies, our inclusion of both study designs provides readers a broader view of the literature.^[@B28],[@B57]^

Pooled effect estimates should ideally be interpreted in light of patient-important effect sizes to facilitate clinical application, but it is unknown what magnitude of motor score improvement represents a minimal important difference (MID).^[@B16],[@B55],[@B58]^ A current multi-center trial of riluzole in TSCI has been powered to detect a 9-point difference,^[@B59]^ and some have considered MIDs of up to 20 points.^[@B24]^ However, others have argued that even very small amounts of motor improvement may be meaningful or that importance may vary depending on the anatomical level and baseline severity of patients\' injuries or other contextual factors.^[@B29],[@B55],[@B60]^ We considered that even small differences could be important to patients, so we conservatively rated down confidence when the 95% CIs failed to exclude any amount of benefit or harm, rather than rating down only if they failed to exclude certain thresholds of MID.^[@B34]^

A multi-variate analysis of 411 participants from The Surgical Timing in Acute Spinal Cord Injury Study (STASCIS) suggested potential confounding between MPS and timing of surgical decompression.^[@B61],[@B62]^ We excluded this study because controlled outcome data were not reported. Although we proposed subgroup analyses based on surgical cointervention to explain potential heterogeneity, surgical timing was infrequently reported and conventional meta-analyses are poorly equipped to statistically adjust for potential confounders. Access to participant-level data from the included studies could facilitate metaregression for this purpose.^[@B63]^

Relation to previous literature {#s016}
-------------------------------

Botelho and colleagues performed a systematic review and concluded that serious potential harms of MPS in patients with acute TSCIs outweighed small potential benefits,^[@B18]^ but Bracken performed a meta-analysis and concluded that MPS improves motor recovery if started within 8 h.^[@B8]^ In comparison to Bracken\'s findings, our point estimate for motor score improvement among all patients was smaller at short-term follow-up and in the direction of harm, rather than benefit, at long-term follow-up; our CIs indicate similar imprecision. Neither of these reviews ensured that the selection of studies was reproducible by using two or more reviewers, neither explored between-study differences in results with pre-specified subgroup hypotheses, and neither addressed confidence in their effect estimates.^[@B1],[@B16]^ Hurlbert and colleagues reported a systematic review performed for the 2013 Update of the Guidelines for the Management of Acute Cervical Spine and Spinal Cord Injuries and provided a level I recommendation against MPS.^[@B14],[@B15]^ Their recommendation cited a lack of compelling evidence from RCTs or controlled observational studies to support clinical benefit and consistent evidence to suggest harm, including indirect evidence of increased mortality from an RCT of 10,008 participants with head injuries.^[@B64]^

Our meta-analysis advances current understanding because it is the first to incorporate the GRADE approach for evaluating confidence in the pooled effect estimates. Confidence ratings are important because they inform evidence users about the quality of the evidence available for clinical decision making by transparently integrating study design, risk of bias, imprecision, inconsistency, indirectness, and publication bias.^[@B16]^ The GRADE approach has been adopted by more than 70 major health research organizations, including the Cochrane Collaboration, the World Heath Organization, and the American College of Physicians.^[@B33]^

Our meta-analysis also advances current understanding because it includes recent studies not pooled previously, including two matched cohort studies that were at low risk of bias. Chikuda and colleagues\' report of 812 pairs from a national administrative database in Japan is the largest controlled study of AEs, and Evaniew and colleagues\' report of 44 matched pairs from a national spinal cord injury registry in Canada was the first to adjust for potential confounding owing to patients\' neurological level of injury and baseline severity of impairment.^[@B1],[@B19]^ Other older, but previously overlooked, studies were also retrieved as a result of our broad search strategy and rigorous methodology.^[@B41],[@B52],[@B54]^

Implications {#s017}
------------

Our results support current guideline recommendations against routine administration of MPS for patients with acute TSCIs, but strong recommendations are not warranted.^[@B14],[@B65]^ Guidelines panels must integrate confidence in effect estimates with the balance of desirable and undesirable consequences for alternative management strategies, estimated values and preferences of typical patients, and potential use of health care resources.^[@B66],[@B67]^ MPS did not provide significant long-term benefit, but all of the 95% CIs for motor recovery were compatible with benefit or harm, the effect estimates for gastrointestinal bleeding were conflicting, confidence for all outcomes was low or very low, and the values and preferences of typical patients are likely to be variable.^[@B68]^

Further research could increase confidence in the effect estimates and clarify the influence of potential confounders or effect modifiers, but utilization of MPS has already declined sharply at many centers in the last decade and equipoise among individual clinicians may be lacking. Although some clinicians report belief in efficacy or medicolegal concerns, Hurlbert and colleagues found that more than 75% of Canadian spine surgeons do not prescribe MPS and Schroeder and colleagues found a 37% relative decrease in utilization among members of the Cervical Spine Research Society.^[@B9],[@B10]^ The clinical burden, cost, and multi-center infrastructure required to conduct a well-designed trial may also be prohibitive.

Conclusions {#s018}
===========

Pooled evidence from multiple RCTs and observational studies does not demonstrate a significant long-term benefit for patients with acute TSCIs and suggests that MPS may be associated with increased gastrointestinal bleeding. These findings support current guidelines against routine use, but strong recommendations are not warranted because confidence in the effect estimates is limited. Further research could increase confidence in the effect estimates and clarify the influence of potential confounders or effect modifiers.
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1.  (a) Randomized, controlled trials: Cochrane Collaboration\'s Risk of Bias tool
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1.  (b) Observational studies: Methodological Index for Non-Randomized Studies
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1.  (a) Motor scores at short-term follow-up; long-term data were similar. SE, standard error; MD, mean difference.

2.  (b) Improvement by one grade or more on the Frankel or ASIA Impairment Scale at short-term follow-up; long-term data were similar. SE, standard error; RR= risk ratio.
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1.  (a) Motor score improvement at short-term follow-up.
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1.  (b) Motor score improvement at long-term follow-up.
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1.  (c) Improvement by one grade or more on the Frankel or ASIA Impairment Scale at short-term follow-up.

![](fig-9){#f9}

1.  (d) Improvement by one grade or more on the Frankel or ASIA Impairment Scale at long-term follow-up. ASIA, American Spinal Injury Association.
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1.  (a) Motor score improvement at short-term follow-up with results of study that required estimation of missing SDs (Ito and colleagues, 2009) omitted.
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1.  (b) Motor score improvement at long-term follow-up with results of study that required estimation of missing SDs (Heary and colleagues, 1997) omitted.
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1.  (c) Improvement by one grade or more on the Frankel or ASIA Impairment. Scale at short-term follow-up with results of study that reported follow-up as time of discharge (Gerhart and colleagues, 1995) omitted.
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1.  (d) Improvement by one grade or more on the Frankel or ASIA Impairment Scale at long-term follow-up with results of study that did not report follow-up duration (Gäbler and colleagues, 1995) omitted. SDs, standard deviations; ASIA, American Spinal Injury Association.
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